QBiotics Group
- Biotech or pharma, therapeutic R&D
QBiotics is an Australian life sciences company that connects scientific discovery, development and commercialisation to harness the power of nature to treat high unmet need diseases and identify small molecules with the greatest potential for pharmaceutical advancement.
QBiotics’ current focus is in two key areas including cancer and chronic wounds. The company also has an early-stage antibiotics programme.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of tumours. Two Phase II clinical trials in soft tissue sarcomas (STSs) or head and neck cancers (HNCs) are ongoing. Tigilanol tiglate was granted Orphan Drug Designation by the FDA for the treatment of STS in Feb 2024.
EBC-1013 our lead wound healing molecule targets multiple pathways to accelerate healing to improve outcomes in complex wounds. Phase 1 trial is currently recruiting in venous leg ulcers and holds promise for diabetic foot ulcers and burns.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}